Clinical Trials · NCT00223691

Treatment of Orthostatic Hypotension in Autonomic Failure

CompletedPhase 1Octreotide (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Vanderbilt University
Enrollment
389
Start date
Mar 2002
Locations
1 site, United States
Primary endpoint
Increase in seated systolic blood pressure 1-hr post drug compared to baseline.
View Octreotide compound reference